In this study, we targeted both NF-κB canonical (p65) and noncanonical (p100) pathways in two distinct tumor models to define the utility of systemically delivered siRNA to exert focal control of ATLL at the tumor site. This evidence concerns the gene NFKB1 and neoplasm.